Wealth Enhancement Advisory Services, LLC Viking Therapeutics, Inc. Call Options Transaction History
Wealth Enhancement Advisory Services, LLC
- $46.2 Billion
- Q4 2024
Call Options
1 transactions
Others Institutions Holding VKTX
# of Institutions
471Shares Held
66.4MCall Options Held
5.88MPut Options Held
3.83M-
Vanguard Group Inc Valley Forge, PA10.2MShares$310 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$184 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$150 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$79.1 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$65.8 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.34B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...